Published in Proc Natl Acad Sci U S A on June 03, 2009
Rapamycin-induced insulin resistance is mediated by mTORC2 loss and uncoupled from longevity. Science (2012) 6.69
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
An emerging role of mTOR in lipid biosynthesis. Curr Biol (2009) 3.50
mTOR complex 2 signaling and functions. Cell Cycle (2011) 2.66
Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue. Diabetes (2010) 2.65
Fat cell-specific ablation of rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes (2010) 2.30
Targeting mTOR: prospects for mTOR complex 2 inhibitors in cancer therapy. Oncogene (2010) 2.22
mTOR: a pharmacologic target for autophagy regulation. J Clin Invest (2015) 1.61
A Central role for mTOR in lipid homeostasis. Cell Metab (2013) 1.57
WNT-LRP5 signaling induces Warburg effect through mTORC2 activation during osteoblast differentiation. Cell Metab (2013) 1.51
Ablation of the mTORC2 component rictor in brain or Purkinje cells affects size and neuron morphology. J Cell Biol (2013) 1.35
Identification of Akt-independent regulation of hepatic lipogenesis by mammalian target of rapamycin (mTOR) complex 2. J Biol Chem (2012) 1.33
The complexes of mammalian target of rapamycin. Curr Protein Pept Sci (2010) 1.33
Chronic mTOR inhibition by rapamycin induces muscle insulin resistance despite weight loss in rats. Br J Pharmacol (2012) 1.32
An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development (2011) 1.27
mTOR-dependent cell survival mechanisms. Cold Spring Harb Perspect Biol (2012) 1.24
Hot topics in aging research: protein translation, 2009. Aging Cell (2009) 1.24
A novel adipose-specific gene deletion model demonstrates potential pitfalls of existing methods. Mol Endocrinol (2012) 1.13
Rapamycin-induced metabolic defects are reversible in both lean and obese mice. Aging (Albany NY) (2014) 1.12
The Mechanistic Target of Rapamycin: The Grand ConducTOR of Metabolism and Aging. Cell Metab (2016) 1.10
Deletion of Rictor in neural progenitor cells reveals contributions of mTORC2 signaling to tuberous sclerosis complex. Hum Mol Genet (2012) 1.10
Nutrient/TOR-dependent regulation of RNA polymerase III controls tissue and organismal growth in Drosophila. EMBO J (2012) 1.08
Targeting TOR dependence in cancer. Oncotarget (2010) 1.07
mTORC2 in the center of cancer metabolic reprogramming. Trends Endocrinol Metab (2014) 1.05
mTOR complex 2 regulates proper turnover of insulin receptor substrate-1 via the ubiquitin ligase subunit Fbw8. Mol Cell (2012) 1.03
Mechanistic target of rapamycin (Mtor) is essential for murine embryonic heart development and growth. PLoS One (2013) 0.99
BSTA promotes mTORC2-mediated phosphorylation of Akt1 to suppress expression of FoxC2 and stimulate adipocyte differentiation. Sci Signal (2013) 0.97
Constitutive activation with overexpression of the mTORC2-phospholipase D1 pathway in uterine leiomyosarcoma and STUMP: morphoproteomic analysis with therapeutic implications. Int J Clin Exp Pathol (2010) 0.96
Alcohol-induced modulation of rictor and mTORC2 activity in C2C12 myoblasts. Alcohol Clin Exp Res (2011) 0.95
Validation of reference genes for the relative quantification of gene expression in human epicardial adipose tissue. PLoS One (2012) 0.94
Major involvement of mTOR in the PPARγ-induced stimulation of adipose tissue lipid uptake and fat accretion. J Lipid Res (2012) 0.92
Mechanistic target of rapamycin controls homeostasis of adipogenesis. J Lipid Res (2013) 0.92
Rictor/mTORC2 loss in the Myf5 lineage reprograms brown fat metabolism and protects mice against obesity and metabolic disease. Cell Rep (2014) 0.91
mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell Res (2015) 0.89
Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med (2014) 0.88
Liver clock protein BMAL1 promotes de novo lipogenesis through insulin-mTORC2-AKT signaling. J Biol Chem (2014) 0.88
Regulation of fatty acid metabolism by mTOR in adult murine hearts occurs independently of changes in PGC-1α. Am J Physiol Heart Circ Physiol (2013) 0.87
Loss of mTOR signaling affects cone function, cone structure and expression of cone specific proteins without affecting cone survival. Exp Eye Res (2015) 0.86
Recent Advances in Adipose mTOR Signaling and Function: Therapeutic Prospects. Trends Pharmacol Sci (2015) 0.85
Deletion of Irs2 causes reduced kidney size in mice: role for inhibition of GSK3beta? BMC Dev Biol (2010) 0.84
Adipose tissue mTORC2 regulates ChREBP-driven de novo lipogenesis and hepatic glucose metabolism. Nat Commun (2016) 0.83
Regulation of insulin receptor substrate-1 by mTORC2 (mammalian target of rapamycin complex 2). Biochem Soc Trans (2013) 0.81
Targeting tissue-specific metabolic signaling pathways in aging: the promise and limitations. Protein Cell (2014) 0.80
In vivo evidence for mTORC2-mediated actin cytoskeleton rearrangement in neurons. Bioarchitecture (2014) 0.80
Conditional disruption of rictor demonstrates a direct requirement for mTORC2 in skin tumor development and continued growth of established tumors. Carcinogenesis (2015) 0.80
Rapamycin: An InhibiTOR of Aging Emerges From the Soil of Easter Island. J Gerontol A Biol Sci Med Sci (2016) 0.80
mTORC2 sustains thermogenesis via Akt-induced glucose uptake and glycolysis in brown adipose tissue. EMBO Mol Med (2016) 0.79
TORC2 signaling antagonizes SKN-1 to induce C. elegans mesendodermal embryonic development. Dev Biol (2013) 0.79
mTORC2 and AMPK differentially regulate muscle triglyceride content via Perilipin 3. Mol Metab (2016) 0.79
Secreted IGFBP5 mediates mTORC1-dependent feedback inhibition of IGF-1 signalling. Nat Cell Biol (2016) 0.78
Phosphoinositide-dependent kinase 1 and mTORC2 synergistically maintain postnatal heart growth and heart function in mice. Mol Cell Biol (2014) 0.78
Judicious Toggling of mTOR Activity to Combat Insulin Resistance and Cancer: Current Evidence and Perspectives. Front Pharmacol (2016) 0.77
Detection of QTL for traits related to adaptation to sub-optimal climatic conditions in chickens. Genet Sel Evol (2017) 0.75
Mtor-Fanconi Anemia DNA Damage Repair Pathway in Cancer. J Oncobiomarkers (2015) 0.75
Adipocyte-specific deletion of mTOR inhibits adipose tissue development and causes insulin resistance in mice. Diabetologia (2016) 0.75
Comment on: Kumar et al. Fat cell-specific ablation of Rictor in mice impairs insulin-regulated fat cell and whole-body glucose and lipid metabolism. Diabetes 2010;59:1397-1406. Diabetes (2011) 0.75
Insulin growth factor binding protein 2 mediates the progression of lymphangioleiomyomatosis. Oncotarget (2017) 0.75
Acid sphingomyelinase deficiency in Western diet-fed mice protects against adipocyte hypertrophy and diet-induced liver steatosis. Mol Metab (2017) 0.75
Isopsoralen-mediated suppression of bone marrow adiposity and attenuation of the adipogenic commitment of bone marrow-derived mesenchymal stem cells. Int J Mol Med (2017) 0.75
Autocrine effect of vascular endothelial growth factor-A is essential for mitochondrial function in brown adipocytes. Metabolism (2015) 0.75
Akt kinase C-terminal modifications control activation loop dephosphorylation and enhance insulin response. Biochem J (2015) 0.75
Growth factor, energy and nutrient sensing signalling pathways in metabolic ageing. Biogerontology (2017) 0.75
TOR-mediated regulation of metabolism in aging. Aging Cell (2017) 0.75
Somatic growth, aging, and longevity. NPJ Aging Mech Dis (2017) 0.75
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science (2005) 38.99
TOR signaling in growth and metabolism. Cell (2006) 35.29
Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell (2006) 18.36
mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell (2002) 18.22
Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell (1994) 17.58
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell (2002) 11.50
Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1. Dev Cell (2006) 11.48
SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell (2006) 10.50
Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40. Nat Cell Biol (2007) 8.07
mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1). Biochem J (2008) 7.18
Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci U S A (2003) 6.82
mTOR.RICTOR is the Ser473 kinase for Akt/protein kinase B in 3T3-L1 adipocytes. J Biol Chem (2005) 5.62
A nutrient sensor mechanism controls Drosophila growth. Cell (2003) 5.61
Multiallelic disruption of the rictor gene in mice reveals that mTOR complex 2 is essential for fetal growth and viability. Dev Cell (2006) 5.19
Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab (2008) 4.91
Essential function of TORC2 in PKC and Akt turn motif phosphorylation, maturation and signalling. EMBO J (2008) 4.79
Identification of Sin1 as an essential TORC2 component required for complex formation and kinase activity. Genes Dev (2006) 4.78
The mammalian target of rapamycin complex 2 controls folding and stability of Akt and protein kinase C. EMBO J (2008) 4.49
Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab (2008) 4.36
Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans. Genes Dev (2009) 3.42
mTOR and the control of whole body metabolism. Curr Opin Cell Biol (2009) 2.52
Muscle-specific deletion of rictor impairs insulin-stimulated glucose transport and enhances Basal glycogen synthase activity. Mol Cell Biol (2007) 2.32
Rictor/TORC2 regulates Caenorhabditis elegans fat storage, body size, and development through sgk-1. PLoS Biol (2009) 2.15
TOR regulation of AGC kinases in yeast and mammals. Biochem J (2008) 2.13
Autocrine IGF-1 action in adipocytes controls systemic IGF-1 concentrations and growth. Diabetes (2008) 1.97
Lipid metabolic enzymes: emerging drug targets for the treatment of obesity. Nat Rev Drug Discov (2004) 1.64
Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol (2005) 1.56
Control of growth by the somatropic axis: growth hormone and the insulin-like growth factors have related and independent roles. Annu Rev Physiol (2001) 1.54
Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. Endocrinology (2006) 1.25
Biology of insulin-like growth factors in development. Birth Defects Res C Embryo Today (2003) 1.23
Metabolic effects of IGF-I deficiency: lessons from mouse models. Pediatr Endocrinol Rev (2005) 0.96
The interplay between nutrients and the adipose tissue. Proc Nutr Soc (2007) 0.88
TOR signaling in growth and metabolism. Cell (2006) 35.29
Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell (2006) 19.16
Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature (2004) 12.36
Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol (2004) 12.12
Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell (2002) 11.59
AMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity. Nature (2009) 10.59
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation. Nature (2006) 9.36
TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91
Sch9 is a major target of TORC1 in Saccharomyces cerevisiae. Mol Cell (2007) 5.67
Specific SIRT1 activation mimics low energy levels and protects against diet-induced metabolic disorders by enhancing fat oxidation. Cell Metab (2008) 5.44
Skeletal muscle-specific ablation of raptor, but not of rictor, causes metabolic changes and results in muscle dystrophy. Cell Metab (2008) 4.91
Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest (2004) 4.65
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Adipose-specific knockout of raptor results in lean mice with enhanced mitochondrial respiration. Cell Metab (2008) 4.36
SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell (2002) 4.31
TOR regulates ribosomal protein gene expression via PKA and the Forkhead transcription factor FHL1. Cell (2004) 4.21
Mitonuclear protein imbalance as a conserved longevity mechanism. Nature (2013) 4.18
Sirt5 is a NAD-dependent protein lysine demalonylase and desuccinylase. Science (2011) 4.16
Regulation of circadian behaviour and metabolism by REV-ERB-α and REV-ERB-β. Nature (2012) 4.15
PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr Opin Lipidol (2009) 4.09
Rapamycin passes the torch: a new generation of mTOR inhibitors. Nat Rev Drug Discov (2011) 4.05
Activation of peroxisome proliferator-activated receptor delta induces fatty acid beta-oxidation in skeletal muscle and attenuates metabolic syndrome. Proc Natl Acad Sci U S A (2003) 4.03
Tor signalling in bugs, brain and brawn. Nat Rev Mol Cell Biol (2003) 3.97
A guide to analysis of mouse energy metabolism. Nat Methods (2011) 3.82
The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. Cell (2013) 3.50
International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors. Pharmacol Rev (2006) 3.48
Interdependence of AMPK and SIRT1 for metabolic adaptation to fasting and exercise in skeletal muscle. Cell Metab (2010) 3.46
Activation of mTORC2 by association with the ribosome. Cell (2011) 3.38
The expanding TOR signaling network. Curr Opin Cell Biol (2005) 3.30
Target of rapamycin (TOR) in nutrient signaling and growth control. Genetics (2011) 3.28
The secret life of NAD+: an old metabolite controlling new metabolic signaling pathways. Endocr Rev (2009) 3.23
Mature-onset obesity and insulin resistance in mice deficient in the signaling adapter p62. Cell Metab (2006) 3.22
The NAD(+) precursor nicotinamide riboside enhances oxidative metabolism and protects against high-fat diet-induced obesity. Cell Metab (2012) 3.18
Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism. Obesity (Silver Spring) (2009) 3.15
Endocrine functions of bile acids. EMBO J (2006) 3.03
Nuclear receptors and the control of metabolism. Annu Rev Physiol (2002) 3.00
Regulation of PGC-1α, a nodal regulator of mitochondrial biogenesis. Am J Clin Nutr (2011) 2.98
Role of mTOR in podocyte function and diabetic nephropathy in humans and mice. J Clin Invest (2011) 2.90
The TOR-controlled transcription activators GLN3, RTG1, and RTG3 are regulated in response to intracellular levels of glutamine. Proc Natl Acad Sci U S A (2002) 2.87
Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell (2012) 2.82
NCoR1 is a conserved physiological modulator of muscle mass and oxidative function. Cell (2011) 2.75
mTOR signaling in disease. Curr Opin Cell Biol (2011) 2.73
mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice. J Clin Invest (2011) 2.72
E2Fs regulate adipocyte differentiation. Dev Cell (2002) 2.71
Elucidating TOR signaling and rapamycin action: lessons from Saccharomyces cerevisiae. Microbiol Mol Biol Rev (2002) 2.69
Sirtuins: the 'magnificent seven', function, metabolism and longevity. Ann Med (2007) 2.64
The retinoblastoma-histone deacetylase 3 complex inhibits PPARgamma and adipocyte differentiation. Dev Cell (2002) 2.61
Impaired expression of peroxisome proliferator-activated receptor gamma in ulcerative colitis. Gastroenterology (2003) 2.59
mTOR in aging, metabolism, and cancer. Curr Opin Genet Dev (2013) 2.53
mTOR and the control of whole body metabolism. Curr Opin Cell Biol (2009) 2.52
Quantitative phosphoproteomics reveal mTORC1 activates de novo pyrimidine synthesis. Science (2013) 2.44
Tor2 directly phosphorylates the AGC kinase Ypk2 to regulate actin polarization. Mol Cell Biol (2005) 2.44
Transcriptional coregulators in the control of energy homeostasis. Trends Cell Biol (2007) 2.40
Sirtuin functions in health and disease. Mol Endocrinol (2007) 2.38
Synergy between LRH-1 and beta-catenin induces G1 cyclin-mediated cell proliferation. Mol Cell (2004) 2.31
Muscle inactivation of mTOR causes metabolic and dystrophin defects leading to severe myopathy. J Cell Biol (2009) 2.30
Activation of the RAS/cyclic AMP pathway suppresses a TOR deficiency in yeast. Mol Cell Biol (2004) 2.26
Adipocyte NCoR knockout decreases PPARγ phosphorylation and enhances PPARγ activity and insulin sensitivity. Cell (2011) 2.26
LRH-1: an orphan nuclear receptor involved in development, metabolism and steroidogenesis. Trends Cell Biol (2004) 2.24
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab (2011) 2.17
Molecular organization of target of rapamycin complex 2. J Biol Chem (2005) 2.15
Growth and aging: a common molecular mechanism. Aging (Albany NY) (2009) 2.13
Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant (2005) 2.09
PRAS40 and PRR5-like protein are new mTOR interactors that regulate apoptosis. PLoS One (2007) 2.07
Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med (2005) 2.06
TOR complex 2: a signaling pathway of its own. Trends Biochem Sci (2009) 2.05
Histone methyl transferases and demethylases; can they link metabolism and transcription? Cell Metab (2010) 2.04
Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: lessons from genetics and pharmacology. Endocr Rev (2004) 2.04
Hepatic mTORC2 activates glycolysis and lipogenesis through Akt, glucokinase, and SREBP1c. Cell Metab (2012) 2.03
The pollutant diethylhexyl phthalate regulates hepatic energy metabolism via species-specific PPARalpha-dependent mechanisms. Environ Health Perspect (2010) 1.98
AMP-activated protein kinase and its downstream transcriptional pathways. Cell Mol Life Sci (2010) 1.95
The metabolic footprint of aging in mice. Sci Rep (2011) 1.93
Where is mTOR and what is it doing there? J Cell Biol (2013) 1.91
Caloric restriction, SIRT1 and longevity. Trends Endocrinol Metab (2009) 1.89
Compensation by the muscle limits the metabolic consequences of lipodystrophy in PPAR gamma hypomorphic mice. Proc Natl Acad Sci U S A (2003) 1.89
Compromised intestinal lipid absorption in mice with a liver-specific deficiency of liver receptor homolog 1. Mol Cell Biol (2007) 1.89
PPAR(gamma) and glucose homeostasis. Annu Rev Nutr (2002) 1.86
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem (2008) 1.85
Targeting sirtuin 1 to improve metabolism: all you need is NAD(+)? Pharmacol Rev (2011) 1.85
SRT1720 improves survival and healthspan of obese mice. Sci Rep (2011) 1.81
The genetic ablation of SRC-3 protects against obesity and improves insulin sensitivity by reducing the acetylation of PGC-1{alpha}. Proc Natl Acad Sci U S A (2008) 1.80
Metabolic networks of longevity. Cell (2010) 1.79
Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study. Physiol Genomics (2008) 1.76
The bile acid membrane receptor TGR5 as an emerging target in metabolism and inflammation. J Hepatol (2010) 1.69
Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol (2004) 1.69
Pharmacological approaches to restore mitochondrial function. Nat Rev Drug Discov (2013) 1.66
Proteins induced by telomere dysfunction and DNA damage represent biomarkers of human aging and disease. Proc Natl Acad Sci U S A (2008) 1.65
Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev (2012) 1.64
Bidirectional crosstalk between endoplasmic reticulum stress and mTOR signaling. Trends Cell Biol (2012) 1.63
Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem (2011) 1.62